Labs / Assays & in vitro testing

GlycoNex, Inc.
New Taipei City, Taiwan · glyconex.com.tw
GMP · GLP
GlycoNex, Inc. is a clinical-stage biopharmaceutical company in New Taipei City, Taiwan. It develops antibody-based therapeutics focused on glycan-directed cancer immunotherapy, and also provides antibody CDMO services and biosimilar development.
They take quote requests by email.
What they offer
Cell line development
Establishes stable cell lines and selects clones for antibody and antibody-based modalities.
Process development and scale-up
Develops and optimizes upstream and downstream processes and scales them up for manufacturing.
GMP-compliant antibody manufacturing
Produces antibodies at 50 L and 200 L scale for Phase 1 clinical supply.
Technology transfer
Provides structured transfer and project management from development to manufacturing.
Analytical development
Supports development, characterization, and quality control of monoclonal antibodies and antibody-drug conjugates.
Glycan isolation and purification
Isolates and purifies glycans from biological materials for characterization, screening, and research.
Glycan semi-synthesis
Prepares and structurally modifies glycans from naturally derived carbohydrate materials.
Glycan structure analysis
Characterizes glycan composition, branching patterns, linkages, and other structural features.
Glycosylation-site analysis
Identifies and characterizes glycosylation sites on proteins.
Monosaccharide analysis
Performs qualitative and quantitative analysis of monosaccharide components in glycans and glycoproteins.
What they work on
- Modalities
- Antibody, Bispecific, ADC, Biosimilar
- Species and models
- GI cancers, solid tumors, osteoporosis, autoimmune disease
- Assays and studies
- SEC-HPLC, CIEX / AEX-HPLC, SDS-PAGE, CE-SDS, RP-HPLC, cIEF, Protein A-HPLC, A280, ELISA, SPR, ADCC / CDC, cell-based assays, and 3 more
- Instruments and platforms
- SEC-HPLC, CIEX / AEX-HPLC, SDS-PAGE, CE-SDS, RP-HPLC, cIEF, Protein A-HPLC, A280, ELISA, SPR, intact-protein MS, CD, and 1 more
- Scale and capacity
- 50 L pilot-scale, 200 L GMP-compliant manufacturing, 50 L + 200 L GMP antibody facility
- Therapeutic areas
- oncology, GI cancers, solid tumors, osteoporosis, autoimmune disease
- Type
- CRDMO
- Sites
- Taipei, Taiwan · New Taipei City, Taiwan
- Quality
- GMP-compliant (antibody manufacturing) · GMP (clinical supply)
- Serves
- Taiwan, Japan
- Founded
- 2001
Similar labs. MYCENAX, Intellective Bio, Transcenta Holding, Alphalyse
Found in a contract services directory. Listing built from glyconex.com.tw. Work here? Claim this listing.